New hope for tough lung cancer: ALPS12 drug trial begins

NCT ID NCT07107490

Recruiting now Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Nov 25, 2025 · Last updated May 22, 2026 · Updated 23 times

Summary

This early-phase study tests a new drug, ALPS12, in about 122 adults with extensive-stage small cell lung cancer that has come back after at least one prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive ALPS12 and be closely monitored for side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ehime University Hospital
RECRUITING

Tōon, Ehime, 791-0295, Japan
Kindai University Hospital
RECRUITING

Sakai, Osaka, 590-0197, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Niigata Cancer Center Hospital
RECRUITING

Niigata, 951-8566, Japan
Queen Mary Hospital
RECRUITING

Hong Kong, Hong Kong
Show Chwan Memorial Hospital
RECRUITING

Changhua, 500, Taiwan

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL-CELL LUNG CANCER